White William Richard

CFO White sells 98,334 shares (70.2% of holdings) for $2,657,249.65 at AKRO; stock off 48.5% from 52-week high

Chief Financial Officer William Richard White executed 4 separate sales totaling 98,334 shares for $2,657,249.65 over two trading days (August 26–27), reducing his stake from 140.1K to 41.8K shares (a 70.2% reduction in holdings). The blended average sale price was $27.02, occurring as the stock trades 48.5% below its 52-week high of $52.25 and the company reported a negative net income of -$56.0M for the most recent fiscal year. His cross-ticker track record shows 12 prior open-market sells with an average 90-day return of +0.1%, indicating marginal timing precision historically. At the AKRO ticker specifically, his 5 prior sales (all in late July 2024) showed mixed near-term outcomes and no measurable 90-day data yet. The substantial reduction in absolute holdings—from 140.1K to 41.8K shares—during a period when the stock is deeply depressed from recent peaks warrants examination of whether execution was driven by liquidity, portfolio rebalancing, or other planned selling protocols.

CFO White sold 161,855 shares for $4.4M across 5 transactions (7/23-7/25), reducing stake by 79.5% to 41,791 shares.

White William Richard, the Chief Financial Officer of AKRO, executed 5 separate sales totaling 161,855 shares for $4,381,866.51 at a blended average price of $27.07 between July 23–25, 2024. This represents a sharp reduction in his holdings from 203,646 shares to 41,791 shares—a 79.5% net decrease in position size. His same-ticker trading history shows 1 of 1 prior measurable sells at AKRO was well-timed on a 90-day basis (the 2023-06-20 sale returned -5.0% over 90 days, capturing a subsequent decline), though the timing context of this current multi-day series and its relationship to recent price momentum (+20.5% over 30 days, +43.5% over 90 days) merits attention. The company reported a net loss of $53,344,000 for its most recent full fiscal year, operating in an unprofitable state.

CFO White sold 34.8K shares (45.4% of holdings) for $976.3K at $28.04 on 2024-07-16; stock now $27.08, down 48.2% from 52-week high.

William Richard White, CFO of Akero Therapeutics, executed 2 separate sales totaling 34,811 shares for $976,274.50, reducing his holdings by 45.4% from 76,602 shares to 41,791 shares. The sales occurred at $28.04 per share on 2024-07-16, slightly above the current price of $27.08. The company is unprofitable with negative net income of $-53,344,000.00 over its most recent full fiscal year. Notably, his single prior sale at AKRO (2023-06-20) registered a 90-day return of -5.0%, demonstrating that timing that sale ahead of subsequent decline, though this current 2024 sale's forward-looking performance remains to be observed. The stock has recovered 22.2% over the past 30 days and 30.4% over 90 days from depressed levels, but remains 48.2% below its 52-week high of $52.25.